These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 15024601

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
    Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Bares R, Claussen CD, Kanz L, Bokemeyer C.
    Cancer; 2002 May 01; 94(9):2353-62. PubMed ID: 12015760
    [Abstract] [Full Text] [Related]

  • 3. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy.
    Johns Putra L, Lawrentschuk N, Ballok Z, Hannah A, Poon A, Tauro A, Davis ID, Hicks RJ, Bolton DM, Scott AM.
    Urology; 2004 Dec 01; 64(6):1202-7. PubMed ID: 15596197
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
    Pfannenberg AC, Oechsle K, Kollmannsberger C, Dohmen BM, Bokemeyer C, Bares R, Vontheim R, Claussen CD.
    Rofo; 2004 Jan 01; 176(1):76-84. PubMed ID: 14712410
    [Abstract] [Full Text] [Related]

  • 7. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
    Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Harper PG, Huddart RA.
    Br J Cancer; 2000 Oct 01; 83(7):863-9. PubMed ID: 10970686
    [Abstract] [Full Text] [Related]

  • 8. FDG PET for detection and therapy control of metastatic germ cell tumor.
    Cremerius U, Effert PJ, Adam G, Sabri O, Zimmy M, Wagenknecht G, Jakse G, Buell U.
    J Nucl Med; 1998 May 01; 39(5):815-22. PubMed ID: 9591582
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up.
    Karapetis CS, Strickland AH, Yip D, Steer C, Harper PG.
    Intern Med J; 2003 May 01; 33(9-10):427-35. PubMed ID: 14511195
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
    De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K, Dohmen BM, Dittrich C, Pont J.
    J Clin Oncol; 2001 Sep 01; 19(17):3740-4. PubMed ID: 11533096
    [Abstract] [Full Text] [Related]

  • 13. [Fluorodeoxyglucose (FDO) positron emission tomography (PET) in testicular germ cell tumors in adults: preliminary French clinical evaluation, development of the technique and its clinical applications].
    Maszelin P, Lumbroso J, Theodore C, Foehrenbach H, Merlet P, Syrota A.
    Prog Urol; 2000 Dec 01; 10(6):1190-9. PubMed ID: 11217558
    [Abstract] [Full Text] [Related]

  • 14. 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse.
    Sanchez D, Zudaire JJ, Fernandez JM, Lopez J, Arocena J, Sanz G, Gimenez M, Rosell D, Robles JE, Berian JM.
    BJU Int; 2002 Jun 01; 89(9):912-6. PubMed ID: 12010239
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients.
    Stephens AW, Gonin R, Hutchins GD, Einhorn LH.
    J Clin Oncol; 1996 May 01; 14(5):1637-41. PubMed ID: 8622082
    [Abstract] [Full Text] [Related]

  • 17. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management.
    Pfannenberg AC, Oechsle K, Bokemeyer C, Kollmannsberger C, Dohmen BM, Bares R, Hartmann JT, Vonthein R, Claussen CD.
    World J Urol; 2004 Jun 01; 22(2):132-9. PubMed ID: 14735310
    [Abstract] [Full Text] [Related]

  • 18. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.
    Hinz S, Schrader M, Kempkensteffen C, Bares R, Brenner W, Krege S, Franzius C, Kliesch S, Heicappel R, Miller K, de Wit M.
    J Urol; 2008 Mar 01; 179(3):936-40; discussion 940. PubMed ID: 18207171
    [Abstract] [Full Text] [Related]

  • 19. Clinical role of FDG PET in evaluation of cancer patients.
    Kostakoglu L, Agress H, Goldsmith SJ.
    Radiographics; 2003 Mar 01; 23(2):315-40; quiz 533. PubMed ID: 12640150
    [Abstract] [Full Text] [Related]

  • 20. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
    Halter G, Buck AK, Schirrmeister H, Wurziger I, Liewald F, Glatting G, Neumaier B, Sunder-Plassmann L, Reske SN, Hetzel M.
    J Thorac Cardiovasc Surg; 2004 Apr 01; 127(4):1093-9. PubMed ID: 15052207
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.